Schonfeld Strategic Advisors LLC Nurix Therapeutics, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $14.6 Billion
- Q2 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 432,289 shares of NRIX stock, worth $11.1 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
432,289
Previous 262,162
64.89%
Holding current value
$11.1 Million
Previous $3.85 Million
134.13%
% of portfolio
0.06%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding NRIX
# of Institutions
182Shares Held
66.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$175 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$113 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$102 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$99.3 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$92.8 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.21B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...